PYC Therapeutics, a clinical-stage biotechnology company, launched a multiple ascending dose study for its investigational drug VP-001, aimed at treating retinitis pigmentosa type 11.

The multiple ascending dose study, conducted across five sites in the USA, will evaluate the safety and efficacy of VP-001 in RP11 patients.

The study involves intravitreal administration of the drug in doses of 30 µg and 75 µg per eye, which were considered safe in the preceding single ascending dose study.

The study participants will receive three doses of VP-001, administered eight weeks apart. The primary endpoints will assess treatment-emergent and serious adverse ocular events over 52 weeks.

Data from this study are anticipated before year-end and will inform the planned registrational trial, which will begin in 2025.